Home/Pipeline/Zasocitinib (TAK-279)

Zasocitinib (TAK-279)

Psoriasis

Phase 3Active

Key Facts

Indication

Psoriasis

Phase

Phase 3

Status

Active

Company

Takeda Pharmaceutical

About Takeda Pharmaceutical

Takeda Pharmaceutical is a purpose-driven, global biopharmaceutical leader with a mission to create better health for people and a brighter future for the world. Its strategy is built on a balanced, diverse portfolio across five core therapeutic areas and a commitment to translating advanced science into life-transforming treatments. The company's 2019 acquisition of Shire plc was a pivotal event, establishing its leadership in rare diseases and significantly expanding its global footprint. Takeda is now executing a transformation to strengthen competitiveness and accelerate future growth, focusing on innovation, operational excellence, and sustainability.

View full company profile

Therapeutic Areas

Gastroenterology and Inflammation Rare Diseases Plasma-Derived Therapies Oncology Neuroscience Vaccines

Other Psoriasis Drugs

Drug	Company	Phase	Status
CYPS317	FibroBiologics	Discovery	Active
PEP Biologic™	Intent Biologics	Unknown	Active
DMT410	Dermata Therapeutics	Preclinical	Exploratory
IL23R program	Acellera	Pre-clinical	Hit-to-Lead
Undisclosed Psoriasis Program	Nepsone	Preclinical	Active
TEM-1657 (Topical)	Temisis	Pre-clinical	Active
TEM-1657 (Oral)	Temisis	Pre-clinical	Active
AIM Platform	Phaim Pharma	Pre-clinical	Active
orismilast	UNION therapeutics	Phase 2	Active
CT-P55	Celltrion	Phase 3	Active
JNJ-77242113	Johnson & Johnson	Phase 3	Active
IL-17A/F Inhibitor (CSPC-2232)	CSPC Pharmaceutical Group Limited	Phase III	Active